Glucose-insulin-potassium
PreclinicalSmall molecule
Glucose-insulin-potassium is one of 18 small molecule programs targeting Cardiac Surgery. It is currently in Preclinical.
2
Indications
3
Total Trials
0
Active Trials
17
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
28 competitors in Cardiac Surgery
#DrugCompanyPhaseTrials
1Farxiga
AstraZenecaApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Ancef
BBaxter Healthcare Corporation
Approved
Pitressin
AAultman Health Foundation
Approved
Naropin
FFresenius Kabi USA, LLC
Approved
Neo-Synephrine
EExela Pharma Sciences, LLC.
Approved
Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 3
Oruvail
WWyeth-Lederle Vaccines
Phase 3
Acanya
PfizerPhase 2
Hydrocortisone Plus Fludrocortisone
NNorthern Jiangsu People's Hospital
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Cardiac Surgery1 trial
Acute1 trial
Reappraisal of GIK in Acute STEMI by Pre-hospital Administration
Unknown status·—·Phase 3·NCT02591927·334 enrolled
Echocardiography1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Glucose-insulin-potassium. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- YYangzhou University